A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs KLH 2109 (Primary)
  • Indications Endometriosis
  • Focus Therapeutic Use
  • Acronyms EDELWEISS
  • Sponsors ObsEva
  • Most Recent Events

    • 23 Jan 2018 Planned End Date changed from 1 May 2019 to 1 Jul 2019.
    • 23 Jan 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Apr 2018.
    • 07 Nov 2017 According to an ObsEva media release, approximately 330 patients are expected to be randomized, and primary endpoint efficacy results continue to be anticipated in mid-2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top